Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 21;72(16):1390-6.
doi: 10.1212/WNL.0b013e3181a187dd.

Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome

Affiliations

Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome

R L Albin et al. Neurology. .

Abstract

Objective: Tourette syndrome (TS) is a common neurodevelopmental disorder marked by tics and behavioral comorbidities. Clinical pharmacology suggests that dopaminergic signaling abnormalities are part of the pathophysiology of TS. Prior molecular imaging studies of nigrostriatal dopaminergic terminal markers report conflicting results. Our goal was to characterize the distribution of nigrostriatal dopaminergic terminals in subjects with TS.

Methods: Thirty-three adult subjects with TS were studied with PET using [11C]dihydrotetrabenazine (DTBZ), a ligand for the type 2 vesicular monoamine transporter, and with [11C] methylphenidate (MP), a ligand for the plasmalemmal dopamine transporter. Subjects were characterized with standard rating instruments for tic severity, obsessive-compulsive behaviors, and attentional deficits.

Results: We found no differences between subjects with TS and control subjects in DTBZ and MP binding in any striatal region. There was no correlation between binding measures and clinical variables. Ventral striatal DTBZ and MP binding distributions in subjects with TS were normal.

Conclusions: We found no evidence of increased striatal dopaminergic innervation in Tourette syndrome (TS). Discrepancy between our present results and those of other studies may be explained by heterogeneity of TS.

PubMed Disclaimer

Figures

None
Figure 1 Average parametric images of [11C]DTBZ and [11C]MP binding in Tourette syndrome (TS) and normal control (NC) subjects Six brain levels through the striatum for both controls (first and fourth rows) and subjects with TS (second and fifth rows) for DTBZ (top) and MP (bottom). Each slice represents the average DVR of the entire subject group (NC = 28, TS = 33). Subtraction images of TS minus control (third and sixth rows) with modest increases in some voxels in TS ventral striatum.
None
Figure 2 Scatterplots of [11C]DTBZ and [11C]MP binding in Tourette syndrome and control ventral striatum DTBZ = [11C]dihydrotetrabenazine; DVR = ratio of volumes of distribution; MP = [11C]methylphenidate.

References

    1. Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006;29:175–182. - PubMed
    1. Leckman JF. Tourette’s syndrome. Lancet 2002;360:1577–1586. - PubMed
    1. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123:425–462. - PubMed
    1. Walkup J, LaBuda MC, Singer HS, Brown J, Riddle MA, Hurko O. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996;59:684–693. - PMC - PubMed
    1. Tourette Syndrome Association International Consortium for Genetics. Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. Am J Hum Genet 2007;80:265–272. - PMC - PubMed

Publication types

MeSH terms